Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs

British Journal of Pharmacology

Volumn 144, Issue 1, 2005, Pages 3-10

  Wennemuth, Gunther ^a   Aumüller, Gerhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiotensin; Calcium; HPCPs; Losartan; Mitogenic; PD 123319; Prostate; Receptor; Stromal

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ION; FURA 2; LOSARTAN;

ANTIBODY DETECTION; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CELL PROLIFERATION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; EMBEDDING; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INHIBITION KINETICS; INTRACELLULAR TRANSPORT; MITOGENESIS; PHOTOMETRY; PRIORITY JOURNAL; PROSTATE EPITHELIUM; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE; STROMA CELL; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOTTING, WESTERN; BUFFERS; CALCIUM; CALCIUM SIGNALING; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; FURA-2; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR FLUID; ISOTONIC SOLUTIONS; LOSARTAN; MALE; MITOSIS; PHOTOMETRY; PROSTATIC HYPERPLASIA; RECEPTOR, ANGIOTENSIN, TYPE 1; STROMAL CELLS; TIME FACTORS;

EID: 13244279432     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706037     Document Type: Article

References (39)

1. ALBRECHT, M., JANSSEN, M., KONRAD, L., RENNEBERG, H. & AUMULLER, G. (2002). Effects of dexamethasone on proliferation of and fibronectin synthesis by human primary prostatic stromal cells in vitro. Andrologia, 34, 11-21.
2. BERRY, S.J., COFFEY, D.S., WALSH, P.C. & EWING, L.L. (1984). The development of human benign prostatic hyperplasia with age. J. Urol., 132, 474-479.
3. BING, C., JOHNSON, I.R. & PIPKIN, F.B. (1996). Angiotensin receptors in myometrium and myometrial vessels from uteri of women during the follicular and luteal phases of the menstrual cycle and in late pregnancy. Clin. Sci. (Lond.), 90, 499-505.
4. BLANKLEY, C.J., HODGES, J.C., KLUTCHKO, S.R., HIMMELSBACH, R.J., CHUCHOLOWSKI, A., CONNOLLY, C.J., NEERGAARD, S.J., VAN NIEUWENHZE, M.S., SEBASTIAN, A. & QUIN III, J. (1991). Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J. Med. Chem., 34, 3248-3260.
5. BONKHOFF, H. & REMBERGER, K. (1998). Morphogenetic concepts of normal and abnormal growth in the human prostate. Virchows Arch., 433, 195-202.
6. DINH, D.T., FRAUMAN, A.G., SOMERS, G.R., OHISHI, M., ZHOU, J., CASLEY, D.J., JOHNSTON, C.I. & FABIANI, M.E. (2002). Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J. Pathol., 196, 213-219.
7. DINH, D.T., FRAUMAN, A.G., SOURIAL, M., CASLEY, D.J., JOHNSTON, C.I. & FABIANI, M.E. (2001). Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology, 142, 1349-1356.
8. DIZ, D.I., JESSUP, J.A., WESTWOOD, B.M., BOSCH, S.M., VINSANT, S., GALLAGHER, P.E. & AVERILL, D.B. (2002). Angiotensin peptides as neurotransmitters/neuromodulators in the dorsomedial medulla. Clin. Exp. Pharmacol. Physiol., 29, 473-482.
9. GOOREN, L. (2003). Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J. Steroid Biochem. Mol. Biol., 85, 349-355.
10. GRECO, S., MUSCELLA, A., ELIA, M.G., SALVATORE, P., STORELLI, C. & MARSIGLIANTE, S. (2002). Activation of angiotensin II type I receptor promotes protein kinase C translocation and cell proliferation in human cultured breast epithelial cells. J. Endocrinol., 174, 205-214.
11. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
12. HAFIZI, S., CHESTER, A.H. & YACOUB, M.H. (1999). Inhibition of human cardiac fibroblast mitogenesis by blockade of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Clin. Exp. Pharmacol. Physiol., 26, 511-513.
13. HELLAWELL, G.O. & BREWSTER, S.F. (2002). Growth factors and their receptors in prostate cancer. BJU Int., 89, 230-240.
14. HUCKLE, W.R. & EARP, H.S. (1994). Regulation of cell proliferation and growth by angiotensin II. Prog. Growth Factor Res., 5, 177-194.
15. JANSSEN, M., ALBRECHT, M., MOSCHLER, O., RENNEBERG, H., FRITZ, B., AUMULLER, G. & KONRAD, L. (2000). Cell lineage characteristics of human prostatic stromal cells cultured in vitro. Prostate, 43, 20-30.
16. KAPLAN, S.A. (2002). Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J. Urol., 168, 1659.
17. KOJIMA, M., NAYA, Y., INOUE, W., UKIMURA, O., WATANABE, M., SAITOH, M. & WATANABE, H. (1997). The American Urological Association symptom index for benign prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate. J. Urol., 157, 2160-2165.
18. KUNERT-RADEK, J. & PAWLIKOWSKI, M. (1992). Angiotensin II stimulation of the rat pituitary tumoral cell proliferation in vitro. Biochem. Biophys. Res. Commun., 183, 27-30.
19. KUWAHARA, M., MIYAJI, T. & TSUBONE, H. (2000). Angiotensin II type 1 receptor-mediated increase in cytosolic Ca(2+) and proliferation in mesothelial cells. Eur. J. Pharmacol., 388, 21-27.
20. LEE, C., SINTICH, S.M., MATHEWS, E.P., SHAH, A.H., KUNDU, S.D., PERRY, K.T., CHO, J.S., ILIO, K.Y., CRONAUER, M.V., JANULIS, L. & SENSIBAR, J.A. (1999). Transforming growth factor-beta in benign and malignant prostate. Prostate, 39, 285-290.
21. MCEWAN, P.E., VINSON, O.P. & KENYON, C.J. (1999). Control of adrenal cell proliferation by AT1 receptors in response to angiotensin II and low-sodium diet. Am. J. Physiol., 276, E303-E309.
22. NASSIS, L., FRAUMAN, A.G., OHISHI, M., ZHUO, J., CASLEY, D.J., JOHNSTON, C.I. & FABIANI, M.E. (2001). Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J. Pathol., 195, 571-579.
23. NATARAJAN, R., GONZALES, N., HORNSBY, P.J. & NADLER, J. (1992). Mechanism of angiotensin II-induced proliferation in bovine adrenocortical cells. Endocrinology, 131, 1174-1180.
24. QU, S., WANG, Z., FANG, Q. & CHEN, G. (2001). Effects of angiotensin II on proliferation and expression of interleukin-6 of human kidney fibroblasts. Hua Xi Yi Ke Da Xue Xue Bao, 32, 379-381.
25. RAY, P.E., BRUGGEMAN, L.A., HORIKOSHI, S., AGUILERA, G. & KLOTMAN, P.E. (1994). Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int., 45, 177-184.
26. RODGERS, K.E., XIONG, S., STEER, R. & DIZEREGA, G.S. (2000). Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells, 18, 287-294.
27. SAYESKI, P.P. & ALI, M.S. (2003). The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Exp. Cell Res., 287, 339-349.
28. SCIARRA, F. & TOSCANO, V. (2000). Role of estrogens in human benign prostatic hyperplasia. Arch. Androl., 44, 213-220.
29. SHAPIRO, E. & LEPOR, H. (1994). The pathophysiology of clinical BPH. Prog. Clin. Biol. Res., 386, 253-261.
30. SHAPIRO, E. (1990). Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia. Urol. Clin. N. Am., 17, 487-493.
31. SHAPIRO, E., HARTANTO, V., PERLMAN, E.J., TANG, R., WANG, B. & LEPOR, H. (1997). Morphometric analysis of pediatric and nonhyperplastic prostate glands: evidence that BPH is not a unique stromal process. Prostate, 33, 177-182.
32. TIMMERMANS, P.B., DUNCIA, J.V., CARINI, D.J., CHIU, A.T., WONG, P.C., WEXLER, R.R. & SMITH, R.D. (1995). Discovery of losartan, the first angiotensin II receptor antagonist. J. Hum. Hypertens., 9 (Suppl 5), S3-S18.
33. UEMURA, H., ISHIGURO, H., NAKAIGAWA, N., NAGASHIMA, Y., MIYOSHI, Y., FUJINAMI, K., SAKAGUCHI, A. & KUBOTA, Y. (2003). Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther., 2, 1139-1147.
34. WENNEMUTH, G., BLOCHER, S., SCHILL, W.B., AUMULLER, G. & MONSEES, T.K. (2003). Bradykinin increases intracellular calcium levels in rat testis peritubular cells via the B2 receptor subtype. Br. J. Pharmacol., 138, 351-358.
35. WENNEMUTH, G., EISOLDT, S., BODE, H.P., RENNEBERG, H., SCHIEMANN, P.J. & AUMULLER, G. (1998). Measurement of calcium influx in surface-fixed single sperm cells: efficiency of different immobilization methods. Andrologia, 30, 141-146.
36. 2+ into mouse sperm. J. Biol. Chem., 275, 21210-21217.
37. YOKOTA, T., HONDA, K., TSURUYA, Y., NOMIYA, M., YAMAGUCHI, O., GOTANDA, K. & CONSTANTINOU, C.E. (2004). Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. Prostate, 58, 156-163.
38. ZHANG, Y.J., YANG, X.S., WU, P.S., LI, X., ZHANG, X.F., CHEN, X.Q. & YU, Z.X. (2003). Effects of angiotensin II and losartan on the growth and proliferation of hepatic stellate cells. Di Yi Jun Yi Da Xue Xue Bao, 23, 219-221, 227.
39. ZHU, Y.S., CAI, L.Q., YOU, X., CORDERO, J.J., HUANG, Y. & IMPERATO-MCGINLEY, J. (2003). Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J. Androl., 24, 681-687.